COMBODY: One-domain antibody multimer with improved avidity

Immunology and Cell Biology

Volumn 88, Issue 6, 2010, Pages 667-675

  Zhu, Xuekai ^a,b   Wang, Lei ^a,b   Liu, Rongzhi ^a   Flutter, Barry ^c   Li, Shenghua ^d   Ding, Jie ^a,b   Tao, Hua ^a   Liu, Changzhen ^a   Sun, Meiyi ^e   Gao, Bin ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e Epigen Biotec   (China)

Author keywords

antibody engineering; avidity; multivalency; single domain antibody; TCR like antibody

Indexed keywords

ANTIBODY; BISPECIFIC ANTIBODY; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN 48; COMBODY; HLA A2 ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIGENS, CD3; BINDING SITES, ANTIBODY; CARCINOEMBRYONIC ANTIGEN; EXTRACELLULAR MATRIX PROTEINS; FEASIBILITY STUDIES; GLYCOPROTEINS; HLA-A2 ANTIGEN; HUMANS; MART-1 ANTIGEN; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS;

EID: 77955660235     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.21     Document Type: Article

References (50)

1. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-357.
2. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-356.
3. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220-4224.
4. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA et al. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 1987; 507: 199-210.
5. Zwick MB, Parren PWHI, Saphire EO, Church S, Wang M, Scott JK et al. Molecular features of the broadly neutralizing immunoglobulin G b required for recognition of human immunodeficiency virus type gp120. J Virol 2003; 77: 5863-5876.
6. Hudson PJ. Recombinant antibody fragments. Curr Opin Biotechnol 1998; 9: 395-402.
7. Inbar D, Hochman J, Givol D. Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci USA 1972; 69: 2659-2662.
8. Better M, Chang CP, Robinson RR, Horwitz AH. Escherichia coli secretion of an active chimeric antibody fragment. Science 1988; 240: 1041-1043.
9. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM et al. Single-chain antigen-binding proteins. Science 1988; 242: 423-426.
10. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989; 341: 544-546. (Pubitemid 19252529)
11. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD et al. Engineered human antibody constant domains with increased stability. J Biol Chem 2009; 284: 14203-14210.
12. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-448.
13. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997; 414: 521-526.
14. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002; 11: 500-515. (Pubitemid 34171255)
15. Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev 2005; 24: 501-519.
16. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002; 98: 456-462.
17. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid singledomain antibody fragments. Appl Microbiol Biotechnol 2007; 77: 13-22.
18. Harmsen MM, Van Solt CB, Fijten HP, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 2005; 23: 4926-4934.
19. Tanha J, Dubuc G, Hirama T, Narang SA, MacKenzie CR. Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J Immunol Methods 2002; 263: 97-109.
20. Deyev SM, Lebedenko EN. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 2008; 30: 904-918.
21. Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H et al. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 2004; 335: 49-56.
22. Stone E, Hirama T, Tanha J, Tong-Sevinc H, Li SH, MacKenzie CR et al. The assembly of single domain antibodies into bispecific decavalent molecules. J Immunol Methods 2007; 318: 88-94.
23. Cohen C, Parry DA. Alpha-helical coiled coils and bundles: how to design an alphahelical protein. Proteins 1990; 7: 1-15.
24. Kammerer RA. Alpha-helical coiled-coil oligomerization domains in extracellular proteins. Matrix Biol 1997; 15: 555- discussion 567-1558
25. Kohn WD, Mant CT, Hodges RS. Alpha-helical protein assembly motifs. J Biol Chem 1997; 272: 2583-2586.
26. Lupas A. Coiled coils: new structures and new functions. Trends Biochem Sci 1996; 21: 375-382.
27. ONeil KT, DeGrado WF. A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 1990; 250: 646-651.
28. Malashkevich VN, Kammerer RA, Efimov VP, Schulthess T, Engel J. The crystal structure of a five-stranded coiled coil in COMP: a prototype ion channel? Science 1996; 274: 761-765.
29. Tomschy A, Fauser C, Landwehr R, Engel J. Homophilic adhesion of E-cadherin occurs by a co-operative two-step interaction of N-terminal domains. EMBO J 1996; 15: 3507-3514.
30. Holler N, Kataoka T, Bodmer JL, Romero P, Romero J, Deperthes D et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237: 159-173.
31. Zhang J, Li Q, Nguyen TD, Tremblay TL, Stone E, To R et al. A pentavalent singledomain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. J Mol Biol 2004; 341: 161-169.
32. Bernardeau K, Gouard S, David G, Ruellan AL, Devys A, Barbet J et al. Assessment of CD involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. Eur J Immunol 2005; 35: 2864-2875.
33. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A from a nonimmunized phage-Fab library. Proc Natl Acad Sci USA 2000; 97: 7969-7974.
34. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. Recombinant antibodies with MHCrestricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit 2003; 16: 324-332.
35. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY et al. Dissecting cytotoxic T cell responses towards the NY-ESO- protein by peptide/MHC-specific antibody fragments. Eur J Immunol 2004; 34: 2919-2929.
36. Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A et al. A superagonist variant of peptide MART1/Melan A27- elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 1999; 59: 301-306.
37. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160: 1750-1758.
38. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004; 64: 2853-2857.
39. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007; 56: 303-317.
40. Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP, Kajava AV. Peptabody a new type of high avidity binding protein. Proc Natl Acad Sci USA 1997; 94: 1663-1668.
41. Wang J, Feng J, Shi M, Qian L, Chen L, Yu M et al. De novo design of ErbB epitope targeting fusion protein stabilized by coiled coil structure. Mol Immunol 2008; 45: 106-116.
42. Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH et al. COMP-Ang1: a designed angiopoietin- variant with nonleaky angiogenic activity. Proc Natl Acad Sci USA 2004; 101: 5547-5552.
43. Efimov VP, Lustig A, Engel J. The thrombospondin-like chains of cartilage oligomeric matrix protein are assembled by a five-stranded alpha-helical bundle between residues and 83. FEBS Lett 1994; 341: 54-58.
44. De Jonge J, Heirman C, de Veerman M, Van Meirvenne S, Moser M, Leo O et al. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti- CD3-anti-idiotype) induces long-term survival in the murine BCL lymphoma model. J Immunol 1998; 161: 1454-1461.
45. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q et al. Bispecific monoclonal antibodies directed to CD and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 1991; 48: 227-233.
46. Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. J Immunol 1997; 159: 5629-5639.
47. Somasundaram C, Arch R, Matzku S, Zoller M. Development of a bispecific F(ab)2 conjugate against the complement receptor CR of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity. Cancer Immunol Immunother 1996; 42: 343-350.
48. Young L, Dong Q. Two-step total gene synthesis method. Nucleic Acids Res 2004; 32: e59.
49. Arakawa F, Kuroki M, Kuwahara M, Senba T, Ozaki H, Matsuoka Y et al. Cloning and sequencing of the VH and V kappa genes of an anti-CD monoclonal antibody, and construction of a mouse/human chimeric antibody. J Biochem 1996; 120: 657-662.
50. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96.